title: Inflammatory mechanisms in ischemic stroke: therapeutic approaches.
abstract: Acute ischemic stroke is the third leading cause of death in industrialized countries and the most frequent cause of permanent disability in adults worldwide. Despite advances in the understanding of the pathophysiology of cerebral ischemia, therapeutic options remain limited. Only recombinant tissue-plasminogen activator (rt-PA) for thrombolysis is currently approved for use in the treatment of this devastating disease. However, its use is limited by its short therapeutic window (three hours), complications derived essentially from the risk of hemorrhage, and the potential damage from reperfusion/ischemic injury. Two important pathophysiological mechanisms involved during ischemic stroke are oxidative stress and inflammation. Brain tissue is not well equipped with antioxidant defenses, so reactive oxygen species and other free radicals/oxidants, released by inflammatory cells, threaten tissue viability in the vicinity of the ischemic core. This review will discuss the molecular aspects of oxidative stress and inflammation in ischemic stroke and potential therapeutic strategies that target neuroinflammation and the innate immune system. Currently, little is known about endogenous counterregulatory immune mechanisms. However, recent studies showing that regulatory T cells are major cerebroprotective immunomodulators after stroke suggest that targeting the endogenous adaptive immune response may offer novel promising neuroprotectant therapies.
authors.affiliation: Global Neuroscience Initiative Foundation, Los Angeles, CA, USA. slakhan@gnif.org
authors.forename: Shaheen E
authors.initials: SE
authors.lastname: Lakhan
authors.forename: Annette
authors.initials: A
authors.lastname: Kirchgessner
authors.forename: Magdalena
authors.initials: M
authors.lastname: Hofer
mesh_terms: D000818:Animals; D018925:Chemokines / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D020782:Matrix Metalloproteinases / Q000378:metabolism; D051267:NF-E2-Related Factor 2 / Q000378:metabolism; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018384:Oxidative Stress; D020127:Recovery of Function; D015427:Reperfusion Injury / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D020521:Stroke / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D018925:Chemokines; D016207:Cytokines; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D018696:Neuroprotective Agents; D020782:Matrix Metalloproteinases